The wide variability in metastasectomy rates (13–43%) and survival (mOS 44–93 months) according to primary tumour location, MMR-status, and mutation status are most probably explained by the differences in RAS-, BRAF-, and MMR-status which, thus, seem most important. Here, BRAF is linked to neoplasm.